Publicações científicas

Hemodynamic Predictors of Survival in Scleroderma-related Pulmonary Arterial Hypertension

Campo A [ES], Mathai SC, Le Pavec J, Zaiman AL, Hummers LK, Boyce D, Housten T, Champion HC, Lechtzin N, Wigley FM, Girgis RE, Hassoun PM.
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States.

Revisão:American Journal of Respiratory and Critical Care Medicine

Data: 25/Mar/2010

Pneumologia

RATIONALE
Pulmonary arterial hypertension (PAH) related to systemic sclerosis (SSc) has a poorer prognosis compared to other forms of PAH for reasons that remain unexplained.

OBJECTIVES
To identify risk factors of mortality in a well characterized cohort of patients with PAH related to systemic sclerosis (SSc-PAH).

METHODS
Seventy-six consecutive SSc patients (64 women and 12 men; mean age 61 +/- 11 years) were diagnosed with PAH by heart catheterization in a single center, starting in January 2000, and followed over time. Kaplan Meier estimates were calculated and mortality risk factors were analyzed.

RESULTS

Forty (53%) patients were in WHO functional class III or IV. Mean pulmonary artery pressure was 41 +/- 11 mmHg, pulmonary vascular resistance (PVR) was 8.6 +/- 5.6 WU, and cardiac index (CI) 2.4 +/- 0.7 L/min/m(2). Median follow-up time was 36 months, with 42 deaths observed. Survival estimates were 85%, 72%, 67%, 50%, and 36% at 1, 2, 3, 4 and 5 years respectively. Multivariate analysis identified PVR (HR 1.10 [95%CI 1.03-1.18; P<0.01]), stroke volume index (HR 0.94 [95%CI 0.89-0.99; P=0.02], and pulmonary arterial capacitance (HR 0.43 [95%CI 0.20-0.91; P=0.03] as strong predictors of survival. An estimated glomerular filtration rate less than 60 mL/min/1.73m(2) portended a 3-fold risk of mortality.

CONCLUSIONS
Our results suggest that specific components of right ventricular dysfunction and renal impairment contribute to increased mortality in SSc-PAH. Understanding the mechanisms of right ventricular dysfunction in response to increased afterload should lead to improved targeted therapy in these patients.

CITAÇÃO DO ARTIGO  Am J Respir Crit Care Med. 2010 Jul 15;182(2):252-60

talvezlhe interesse

QUE TECNOLOGIA UTILIZAMOS? 

A Clínica é o hospital privado com maiores recursos tecnológicos de Espanha, tudo num único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OS NOSSOS
PROFISSIONAIS

Os profissionais da Clínica realizam um trabalho contínuo de investigação e formação, sempre em benefício do paciente.

Imagen profesionales de la Clínica Universidad de Navarra

RAZÕES PARA VIR
À CLÍNICA

Conheça porque é que somos diferentes em relação a outros centros sanitários. Qualidade, rapidez, comodidade e resultados.

Imagen del edificio de la Clínica Universidad de Navarra